If enacted, SF1739 may significantly alter the landscape of healthcare provision in Minnesota by mandating that certain medications and treatments cannot require prior authorization. This change is expected to facilitate quicker and easier access to necessary healthcare services, especially in critical situations such as emergencies. Additionally, the bill introduces a formal structure through which the commissioner of health can approve medications for exemption based on recommendations from the prior authorization commission.
Summary
SF1739 is a legislative act aimed at establishing a prior authorization commission within the Minnesota Department of Health. This commission is tasked with reviewing medications that have high rates of prior authorization denials and recommending which medications should be exempt from these requirements. The objective of the bill is to streamline access to medical treatments, particularly for emergency services, mental health, and substance use disorder treatments, thereby reducing administrative barriers for patients and healthcare providers.
Contention
The discussions surrounding SF1739 revealed some contention among members, particularly regarding the implications for health insurance providers and the regulation of healthcare costs. Supporters argue that reducing prior authorization requirements will improve patient care and account for the urgency often necessary in healthcare scenarios, particularly for mental health and cancer treatments. However, critics express concerns that this could potentially raise healthcare costs overall, as removing prior authorization may lead to increased demand for certain treatments and medications without the prior vetting that these processes provide.
Prior authorization on medications prescribed for antineoplastic cancer treatment prohibition; prior authorization denials based on timing of the provided health care service prohibition; expedited prior authorization review for prescriptions that have previously been authorized or covered requirement
Changes to provisions covering prescription drug prior authorizations, transactions with group purchasers, prescription drug price transparency, health maintenance organizations, network design, coverage for immunizations, access to certain data collected, and obsolete language made.
Standards for utilization review performance modified, cause of action created for wrongful denials of prior authorizations by utilization review organizations, attorney general enforcement provided, fines by commissioner of commerce authorized, and oversight required.